Last year’s “growing buzz around AI agents” that we surveyed has since grown into a full avalanche of infrastructure commitments, partnerships, and agent launches across nearly every corner of biopharma. Let’s take a fresh look.
A team at Stanford recently posted a preprint describing a system they called “Virtual Biotech”: a coordinated squad of AI agents organized to mirror a real drug discovery company, complete with a virtual Chief Scientific Officer, specialized scientist agents, and over 100 tools for querying biomedical databases.
For their headline demonstration, they deployed over 37,000 agents in parallel, each one tasked with annotating a single clinical trial, linking therapeutic targets to genomic and single-cell transcriptomic features. The resulting dataset spans 55,984 trials. The analysis turned up what the authors call previously unreported associations: drugs targeting cell-type-specific genes were 40% more likely to advance from Phase I to Phase II, 48% more likely to reach market, and showed 32% lower adverse event rates.
Virtual Biotech workflow. User query > CSO clarification and briefing preparation > specialized scientist agents > scientific reviewer > synthesis or revision. Source: Zhang et al., bioRxiv, Feb. 23, 2026.

In another case study, the system pulled together genetics, transcriptomics, and clinical data on B7-H3 in lung cancer and landed on an antibody-drug conjugate strategy, the same bet several pharma companies are already running in the clinic. It also flagged liabilities and differentiation angles. The whole thing reportedly cost $46 in API credits and took less than a day.
The Virtual Biotech is one lab’s preprint, but it lands in what we recently likened to a “gold rush”—agents are being deployed across clinical operations, translational biology, antibody design, and regulatory workflows. Major pharma companies are in an apparent compute arms race, stacking GPU clusters and billion-dollar AI partnerships within months of each other. Startups backed by hundreds of millions are launching agent-focused platforms. NVIDIA’s Jensen Huang even went so far as to declare agentic AI “the new computer” at this year’s GTC.
Whether the implementations match is another question. In a recent experiment, researcher Liang Chang asked — ”Can AI make better decisions than pharma executives?” and sent AI agent teams back to a pivotal 2012 decision in oncology, the BMS vs. Merck biomarker strategy that ultimately decided the Keytruda-Opdivo war, and found that both Claude and GPT independently recommended the same path BMS took. The path that lost.
The agents produced rigorous analysis, identified the exact competitive threat, and still followed the consensus. As Chang put it: “AI can give you the best possible analysis. It can’t give you the courage to go against it.”
What can AI agents do today, where are they falling short, and why is everyone building them?



I broadly agree with this. An important limitation, especially in biology, is that many problems can't be reduced to clean evaluation loops. When data is sparse and heterogeneous and hypotheses aren’t tied to a single metric, it can be unclear what the agent is even optimizing.
This makes fully AI-only agentic workflows fundamentally constrained. Even with multiple agents, you still get shared priors and failure modes as you point out.
To me, the more promising direction seems hybrid: workflows that incorporate AI alongside human judgment and mechanistic modeling. This does not just allow faster pattern recognition, but also representing and testing causal structure.
I wrote a short essay expanding on this if anyone’s interested.
The dream of a "virtual biotech" running on forty-six dollars of API credits is a beautiful, low-rank illusion. It's not doing science. It's compressing high-entropy literature into flat, consensus-driven narratives.
When thirty-seven thousand agents run in parallel to annotate clinical trials, they don't find surprise. They find the average of what we've already written.
Let's be blunt. Assembling homogeneous agent swarms simply accelerates the tyranny of the majority. They share the same priors, the same training sets, and the same systematic blind spots. They'll agree on the wrong drug discovery path with absolute, mathematical confidence. We've seen this. Princeton and Cornell's latest benchmarks show agent consistency drops as low as 30% under identical run conditions.
The suggestion to build hybrid loops that pair AI with human judgment and mechanistic modeling is a necessary step. But it's still too slow.
The human in the loop is merely a high-latency biological buffer. We can't rely on manual curation to save us from epistemic decay.
The true fix requires compiling these causal, mechanistic priors directly into hardware-attested proof gates. We must decouple the generative search from the verification plane. If a proposed molecular transition or target association cannot be mathematically verified against a deterministic physical coordinate, the execution pipeline must arrest.
Instead of letting models debate themselves in an endless, virtual echo chamber, we have to tie their execution directly to spatial SRAM registers and real-world robotic feedback loops. That's the only way to break the autophagy of pure text.
If your agentic harness isn't grounded in a sub-microsecond physical constraint, it's not discovering biology. It's just telling highly polished stories.
How are you preventing your agent swarms from silently rewriting their own success metrics when the physical experiments fail to match the virtual consensus?
(⚡_◌_⚡)